{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:55:06Z","timestamp":1759366506721,"version":"build-2065373602"},"reference-count":84,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.revmed.2022.06.006","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T07:26:08Z","timestamp":1657351568000},"page":"528-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anticorps anti-cytokines\u00a0: quel impact clinique en pathologie humaine\u00a0?"],"prefix":"10.1016","volume":"43","author":[{"given":"L.","family":"Gaigne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Piperoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Banzet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ghellab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"V\u00e9ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Schleinitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ebbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2022.06.006_bib0425","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1586\/1744666X.2014.918848","article-title":"Detection of anti-cytokine antibodies and their clinical relevance","volume":"10","author":"Meager","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0430","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/QCO.0000000000000561","article-title":"Anticytokine autoantibodies leading to infection: early recognition, diagnosis and treatment options","volume":"32","author":"Barcenas-Morales","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.revmed.2022.06.006_bib0435","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10875-011-9621-8","article-title":"Determination of human anticytokine autoantibody profiles using a particle-based approach","volume":"32","author":"Ding","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0440","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/289496a0","article-title":"Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon","volume":"289","author":"Vallbracht","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2022.06.006_bib0445","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF02678552","article-title":"Natural and therapeutically-induced antibodies to cytokines","volume":"10","author":"Revoltella","year":"1998","journal-title":"Biotherapy"},{"key":"10.1016\/j.revmed.2022.06.006_bib0450","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02678216","article-title":"Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action","volume":"10","author":"van der Meide","year":"1997","journal-title":"Biotherapy"},{"key":"10.1016\/j.revmed.2022.06.006_bib0455","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0002-9343(86)90013-6","article-title":"Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A)","volume":"80","author":"Spiegel","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2022.06.006_bib0460","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/1097-0142(19870201)59:3+<668::AID-CNCR2820591317>3.0.CO;2-J","article-title":"Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection","volume":"59","author":"Itri","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2022.06.006_bib0465","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jir.1998.18.345","article-title":"Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a","volume":"18","author":"Antonelli","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.revmed.2022.06.006_bib0470","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1212\/WNL.50.5.1266","article-title":"Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple sclerosis collaborative research group (MSCRG)","volume":"50","author":"Rudick","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2022.06.006_bib0475","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0168-8278(98)80309-7","article-title":"Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C","volume":"28","author":"Leroy","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0480","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1523-1755.2005.00514.x","article-title":"Incidence of recombinant erythropoietin (EPO) hyporesponse. EPO-associated antibodies, and pure red cell aplasia in dialysis patients","volume":"68","author":"Kharagjitsingh","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2022.06.006_bib0485","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5414\/CN109159","article-title":"Evaluation of the safety and immunogenicity of subcutaneous HX575\u00a0epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients","volume":"88","author":"Casadevall","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0490","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-020-00987-3","article-title":"Single-dose pharmacokinetics. pharmacodynamics and immunogenicity, and multiple-dose immunogenicity of INTP5 (Pegfilgrastim Biosimilar) versus reference pegfilgrastim in healthy subjects","volume":"41","author":"Singh","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.revmed.2022.06.006_bib0495","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-5699(90)90068-K","article-title":"Autoantibodies to cytokines--friends or foes?","volume":"11","author":"Bendtzen","year":"1990","journal-title":"Immunol Today"},{"key":"10.1016\/j.revmed.2022.06.006_bib0500","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1172\/JCI115049","article-title":"Chronic neutropenia. A new canine model induced by human granulocyte colony-stimulating factor","volume":"87","author":"Hammond","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2022.06.006_bib0505","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/j.1537-2995.2008.01749.x","article-title":"Epoetin-associated pure red cell aplasia: past, present, and future considerations","volume":"48","author":"McKoy","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2022.06.006_bib0510","doi-asserted-by":"crossref","first-page":"e0179981","DOI":"10.1371\/journal.pone.0179981","article-title":"Prevalence and correlation of cytokine-specific autoantibodies with epidemiological factors and C-reactive protein in 8,972\u00a0healthy individuals: Results from the danish blood donor study","volume":"12","author":"von Stemann","year":"2017","journal-title":"PLoS one"},{"key":"10.1016\/j.revmed.2022.06.006_bib0515","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4049\/jimmunol.144.2.685","article-title":"Natural antibodies to IFN-gamma in man and their increase during viral infection","volume":"144","author":"Caruso","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0520","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/jir.1994.14.159","article-title":"Specific autoantibodies directed against interferon-alpha in pharmaceutically prepared human immunoglobulin preparations","volume":"14","author":"Ross","year":"1994","journal-title":"J Interferon Res"},{"key":"10.1016\/j.revmed.2022.06.006_bib0525","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0162-3109(94)90058-2","article-title":"An anti-IL-2\u00a0antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2","volume":"28","author":"Courtney","year":"1994","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.revmed.2022.06.006_bib0530","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.revmed.2022.06.006_bib0535","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19\u00a0pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.revmed.2022.06.006_bib0540","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1084\/jem.20091983","article-title":"Autoantibodies against IL-17A, IL-17F, and IL-22\u00a0in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I","volume":"207","author":"Puel","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.revmed.2022.06.006_bib0545","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.revmed.2022.06.006_bib0550","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1182\/blood-2010-05-286161","article-title":"Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia","volume":"116","author":"Burbelo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2022.06.006_bib0555","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2018.04.027","article-title":"Recombination activity of human recombination-activating gene 2 (RAG2) mutations and correlation with clinical phenotype","volume":"143","author":"Tirosh","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.revmed.2022.06.006_bib0560","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1172\/JCI80477","article-title":"Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency [published correction appears in J Clin Invest 2016\u00a0Nov 1;126(11):4389]","volume":"125","author":"Walter","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2022.06.006_bib0565","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.jaci.2017.11.014","article-title":"Anticytokine autoantibodies in a patient with a heterozygous NFKB2\u00a0mutation","volume":"141","author":"Ramakrishnan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0570","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.autrev.2015.01.015","article-title":"Emerging clinical phenotypes associated with anti-cytokine autoantibodies","volume":"14","author":"Vincent","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2022.06.006_bib0575","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/cei.12975","article-title":"Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore","volume":"189","author":"Howe","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0580","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/ACI.0000000000000316","article-title":"Anticytokine autoantibodies in infection and inflammation: an update","volume":"16","author":"Barcenas-Morales","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0585","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s002960050073","article-title":"Anti-IL-8\u00a0autoantibodies and complexes in rheumatoid arthritis: polyclonal activation in chronic synovial tissue inflammation","volume":"18","author":"Peichl","year":"1999","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2022.06.006_bib0590","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/art.10497","article-title":"Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus","volume":"46","author":"Hellmich","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2022.06.006_bib0595","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antib5010003","article-title":"Anticytokine autoantibodies: association with infection and immune dysregulation","volume":"5","author":"Knight","year":"2016","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.revmed.2022.06.006_bib0600","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10875-021-00994-9","article-title":"Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19\u00a0pneumonia","volume":"41","author":"de Prost","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0605","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1359-6101(00)00010-1","article-title":"Interferon-gamma and interleukin-12\u00a0pathway defects and human disease","volume":"11","author":"Dorman","year":"2000","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.revmed.2022.06.006_bib0610","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-032713-120222","article-title":"Anticytokine autoantibody-associated immunodeficiency","volume":"32","author":"Browne","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0615","doi-asserted-by":"crossref","first-page":"e5479","DOI":"10.7717\/peerj.5479","article-title":"Epidemiology of and risk factors for extrapulmonary nontuberculous mycobacterial infections in Northeast Thailand","volume":"6","author":"Kham-Ngam","year":"2018","journal-title":"PeerJ"},{"key":"10.1016\/j.revmed.2022.06.006_bib0620","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/cid\/cix996","article-title":"Clinical significance of interferon-\u03b3 neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease","volume":"66","author":"Aoki","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2022.06.006_bib0625","doi-asserted-by":"crossref","first-page":"e3927","DOI":"10.1097\/MD.0000000000003927","article-title":"Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-\u03b3 autoantibodies and disseminated nontuberculous mycobacterial infections","volume":"95","author":"Chi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2022.06.006_bib0630","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1111160","article-title":"Adult-onset immunodeficiency in Thailand and Taiwan","volume":"367","author":"Browne","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2022.06.006_bib0635","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3201\/eid2206.151860","article-title":"Interferon-\u03b3 Autoantibodies as predisposing factor for nontuberculous mycobacterial infection","volume":"22","author":"Valour","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.revmed.2022.06.006_bib0640","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cid\/ciz786","article-title":"Natural history and evolution of anti-interferon-\u03b3 autoantibody-associated immunodeficiency syndrome in Thailand and the United States","volume":"71","author":"Hong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2022.06.006_bib0645","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2012-08-452482","article-title":"Anti-IFN-\u03b3 autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02\u00a0and HLA-DQB1*05:02\u00a0and the reactivation of latent varicella-zoster virus infection","volume":"121","author":"Chi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2022.06.006_bib0650","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190502","article-title":"Anti-IFN-\u03b3 autoantibodies underlie disseminated talaromyces marneffei infections","volume":"217","author":"Guo","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.revmed.2022.06.006_bib0655","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaci.2015.09.018","article-title":"Anti-IFN-\u03b3 autoantibodies are strongly associated with HLA-DR*15:02\/16:02\u00a0and HLA-DQ*05:01\/05:02\u00a0across Southeast Asia","volume":"137","author":"Ku","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0660","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","article-title":"The role of IL-6\u00a0in host defence against infections: immunobiology and clinical implications","volume":"13","author":"Rose-John","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0665","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/annrheumdis-2012-202768","article-title":"Suppression of elevations in serum C reactive protein levels by anti-IL-6\u00a0autoantibodies in two patients with severe bacterial infections","volume":"72","author":"Nanki","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2022.06.006_bib0670","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.180.1.647","article-title":"Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6","volume":"180","author":"Puel","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0675","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3389\/fimmu.2019.02629","article-title":"Anti-IL6\u00a0autoantibodies in an infant with CRP-less septic shock","volume":"10","author":"Bloomfield","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0680","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/pathogens4030606","article-title":"Interleukin 17-mediated host defense against candida albicans","volume":"4","author":"Sparber","year":"2015","journal-title":"Pathogens"},{"key":"10.1016\/j.revmed.2022.06.006_bib0685","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/imr.12027","article-title":"IL-22, not simply a Th17\u00a0cytokine","volume":"252","author":"Rutz","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.revmed.2022.06.006_bib0690","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1074-7613(01)00218-7","article-title":"GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1","volume":"15","author":"Shibata","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.revmed.2022.06.006_bib0695","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-019-0066-3","article-title":"Pulmonary alveolar proteinosis","volume":"5","author":"Trapnell","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.revmed.2022.06.006_bib0700","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0014-5793(98)01668-8","article-title":"Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor","volume":"442","author":"Tanaka","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.revmed.2022.06.006_bib0705","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1084\/jem.190.6.875","article-title":"Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte\/macrophage colony-stimulating factor","volume":"190","author":"Kitamura","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.revmed.2022.06.006_bib0710","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa062505","article-title":"GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis","volume":"356","author":"Uchida","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2022.06.006_bib0715","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jinf.2012.03.020","article-title":"Opportunistic infections in patients with pulmonary alveolar proteinosis","volume":"65","author":"Punatar","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.revmed.2022.06.006_bib0720","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/cid\/ciu968","article-title":"Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated\/extrapulmonary nocardiosis","volume":"60","author":"Rosen","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2022.06.006_bib0725","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.4049\/jimmunol.1202526","article-title":"Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis","volume":"190","author":"Rosen","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0730","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1365-2567.2000.00949.x","article-title":"Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations","volume":"99","author":"Wadhwa","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.revmed.2022.06.006_bib0735","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI117881","article-title":"High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG","volume":"95","author":"Ross","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2022.06.006_bib0740","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/1043-4666(92)90047-U","article-title":"Effects of human anti-IL-1\u00a0alpha autoantibodies on receptor binding and biological activities of IL-1","volume":"4","author":"Svenson","year":"1992","journal-title":"Cytokine"},{"key":"10.1016\/j.revmed.2022.06.006_bib0745","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0091-6749(91)90335-L","article-title":"Anti-interleukin-1\u00a0alpha autoantibodies in humans: characterization, isotype distribution, and receptor-binding inhibition--higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia)","volume":"88","author":"Saurat","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0750","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2249.1991.tb05740.x","article-title":"Anti-IL-1\u00a0alpha autoantibodies in patients with rheumatic diseases and in healthy subjects","volume":"85","author":"Suzuki","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0755","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2362.1994.tb00991.x","article-title":"Sex- and age-dependency of IgG auto-antibodies against IL-1\u00a0alpha in healthy humans","volume":"24","author":"Hansen","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.revmed.2022.06.006_bib0760","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/1043-4666(93)90026-2","article-title":"High-affinity IgG autoantibodies to IL-6\u00a0in sera of normal individuals are competitive inhibitors of IL-6\u00a0in vitro","volume":"5","author":"Hansen","year":"1993","journal-title":"Cytokine"},{"key":"10.1016\/j.revmed.2022.06.006_bib0765","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1172\/JCI115883","article-title":"Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1\u00a0antibody in normal human serum","volume":"90","author":"Sylvester","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2022.06.006_bib0770","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.febslet.2007.04.029","article-title":"Anti-cytokine autoantibodies are ubiquitous in healthy individuals","volume":"581","author":"Watanabe","year":"2007","journal-title":"FEBS Lett"},{"key":"10.1016\/j.revmed.2022.06.006_bib0775","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood.V91.6.2054","article-title":"Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations","volume":"91","author":"Svenson","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2022.06.006_bib0780","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1182\/blood-2008-05-155689","article-title":"Granulocyte\/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects","volume":"113","author":"Uchida","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2022.06.006_bib0785","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-3083.1989.tb01204.x","article-title":"Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections","volume":"30","author":"Fomsgaard","year":"1989","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0790","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0022-1759(91)90361-I","article-title":"Failure to demonstrate TNF alpha-specific autoantibodies in human sera by ELISA and western blot","volume":"139","author":"Leusch","year":"1991","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.revmed.2022.06.006_bib0795","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/iid3.109","article-title":"IL-6-specific autoantibodies among APECED and thymoma patients","volume":"4","author":"K\u00e4rner","year":"2016","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.revmed.2022.06.006_bib0800","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/eji.201041253","article-title":"Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications","volume":"41","author":"Kisand","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0805","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.1365-2567.1999.00806.x","article-title":"Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease","volume":"97","author":"Meager","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.revmed.2022.06.006_bib0810","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0140-6736(05)64012-3","article-title":"Spontaneous neutralising antibodies to interferon--alpha and interleukin-12\u00a0in thymoma-associated autoimmune disease","volume":"350","author":"Meager","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2022.06.006_bib0815","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/cells9010072","article-title":"Anti-cytokine autoantibodies in systemic lupus erythematosus","volume":"9","author":"Howe","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.revmed.2022.06.006_bib0820","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/art.39607","article-title":"Distinct functions of autoantibodies against interferon in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-018-0218-1","article-title":"Clinical features of Sj\u00f6gren's syndrome patients with autoantibodies against interferons","volume":"8","author":"Burbelo","year":"2019","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.revmed.2022.06.006_bib0830","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF01541394","article-title":"Increased incidence of neutralizing autoantibodies against interleukin-1\u00a0alpha (IL-1\u00a0alpha) in nondestructive chronic polyarthritis","volume":"16","author":"Jouvenne","year":"1996","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.revmed.2022.06.006_bib0835","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/ard.2003.019992","article-title":"Prognostic laboratory markers of joint damage in rheumatoid arthritis","volume":"64","author":"Lindqvist","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2022.06.006_bib0840","first-page":"1492","article-title":"Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis","volume":"28","author":"Sakata","year":"2001","journal-title":"J Rheumatol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322005434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322005434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:45:29Z","timestamp":1759337129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866322005434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0248866322005434"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2022.06.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticorps anti-cytokines\u00a0: quel impact clinique en pathologie humaine\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2022.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}